MCS110 + carboplatin + gemcitabine
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Triple Negative Breast Cancer (TNBC) With High TAMs
Conditions
Advanced Triple Negative Breast Cancer (TNBC) With High TAMs
Trial Timeline
Aug 10, 2015 → Mar 23, 2020
NCT ID
NCT02435680About MCS110 + carboplatin + gemcitabine
MCS110 + carboplatin + gemcitabine is a phase 2 stage product being developed by Novartis for Advanced Triple Negative Breast Cancer (TNBC) With High TAMs. The current trial status is completed. This product is registered under clinical trial identifier NCT02435680. Target conditions include Advanced Triple Negative Breast Cancer (TNBC) With High TAMs.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Triple Negative Breast Cancer (TNBC) With High TAMs were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02435680 | Phase 2 | Completed |
Competing Products
20 competing products in Advanced Triple Negative Breast Cancer (TNBC) With High TAMs